A5059130821- Melanoma and MAPK Pathways
- Autoimmune Bullous Skin Diseases
- Cancer Immunotherapy and Biomarkers
- Sarcoidosis and Beryllium Toxicity Research
- Cutaneous Melanoma Detection and Management
- Drug-Induced Adverse Reactions
- Chronic Lymphocytic Leukemia Research
- CAR-T cell therapy research
- Cutaneous lymphoproliferative disorders research
- Eosinophilic Disorders and Syndromes
- Autoimmune and Inflammatory Disorders
- Urticaria and Related Conditions
- Cancer Diagnosis and Treatment
- Dermatological and COVID-19 studies
- Oral Health Pathology and Treatment
- Mycobacterium research and diagnosis
- CNS Lymphoma Diagnosis and Treatment
- Viral-associated cancers and disorders
- Acne and Rosacea Treatments and Effects
- Brain Metastases and Treatment
- Skin Diseases and Diabetes
- Genital Health and Disease
- Microscopic Colitis
- Mast cells and histamine
- Synthesis and biological activity
Université Paris Cité
2016-2024
Assistance Publique – Hôpitaux de Paris
2017-2024
Hôpital Cochin
2014-2024
Lymphoma Study Association
2024
Sorbonne Paris Cité
2019-2023
Inserm
2016-2022
Institut Cochin
2016-2022
Hôpital Bichat-Claude-Bernard
2020-2022
Délégation Paris 5
2017-2019
Descartes (Belgium)
2018
Checkpoint inhibitors have significantly improved the prognosis of patients with advanced melanoma. These cancer immunotherapy drugs specific endocrine autoimmune toxicity. We describe a case an adrenal insufficiency secondary to pembrolizumab, anti-programmed cell death-1 monoclonal antibody. Moreover, this polyendocrinopathy resulting from pembrolizumab as occurred after thyroiditis. A 55-year-old female was started on for metastatic choroidal Five months initiation, she suffered...
Propionibacterium acnes (P. acnes) is an anaerobic, Gram-positive bacteria encountered in inflammatory acne lesions, particularly the pilosebaceous follicle. P. triggers a strong immune response involving keratinocytes, sebocytes and monocytes, target cells during development. Lipoteicoic acid peptidoglycan induce reaction, but no surface protein interacting with Toll-like receptors has been identified. proteins have extracted by lithium stripping shown to CXCL8 production...
<b><i>Background:</i></b> Vemurafenib, a BRAF inhibitor, is first-line treatment for inoperable melanoma. Sarcoidosis has never been reported in patients on vemurafenib. <b><i>Objectives:</i></b> We describe 5 cases of sarcoidosis treated with <b><i>Methods:</i></b> Seventy receiving vemurafenib <i>BRAF</i>-mutated stage III or IV melanoma were our centre. <b><i>Results:</i></b> Five...
Immune-checkpoint inhibitors (ICIs) targeting cytotoxic T lymphocyte-associated antigen-4 and programmed cell death ligand-1) are associated with several immune-related neurological disorders. Cases of meningitis related to ICIs poorly described in literature probably underestimated. Several guidelines available for the acute management these adverse events, but safety resuming patients remains unclear. We conducted a retrospective case series that occurred between October 1 2015 31 2019 two...
Patients treated with dabrafenib/trametinib (DAB/TRA) exhibit a large interindividual variability in clinical outcomes. The aims of this study were to characterize the pharmacokinetics DAB, hydroxy-dabrafenib (OHD), and TRA BRAF-mutated patients investigate exposure–response relationship for toxicity efficacy metastatic melanoma (MM) patients. Univariate Fisher Wilcoxon models including drug systemic exposure (area under plasma concentration curve, AUC) used identify prognostic factors onset...
Sarcoidosis is a systemic disease that affects the skin in about 25% of patients. The treatment cutaneous sarcoidosis guided by extent lesions, associated symptoms and organ involvement. To evaluate rates response to various potential first-line treatments for during year following initiation. This retrospective multicentre study included 120 patients with sarcoidosis. Treatment was assessed retrospectively from patients' medical records. Univariate logistic regression analysis, an...
A new treatment for cystic fibrosis combining 3 CFTR modulators-elexacaftor (ELX), tezacaftor (TEZ), and ivacaftor (IVA)-has recently been approved treatment. The cutaneous adverse effects following with this combination are poorly described in the literature.
Positron emission tomography/computed tomography with fluorodeoxyglucose (F-18) (FDG PET/CT) is increasingly used in Kaposi sarcoma (KS), but its value has not been assessed.In this study, we aimed to evaluate the diagnostic accuracy of FDG PET/CT define extent disease KS.Consecutive patients KS referred our department for were included. The cutaneous and extra-cutaneous staging was assessed on a per lesion basis compared obtained from clinical examination, standard imaging, endoscopy,...
Combined BRAF and MEK inhibition is one of the first-line treatment strategies for patients with advanced BRAF-mutant melanoma. Sarcoid-like reactions (SLRs) have occasionally been described melanoma systemic treatments such as immunotherapy or inhibitor vemurafenib, but very few cases reported dabrafenib trametinib. Our aim was to better characterize SLR induced by this combination. We conducted a monocentric retrospective observational study among treated trametinib from January 2015 March...
The characteristics of patients with dermatitis herpetiformis (DH) in France is poorly documented. Furthermore, the risk fractures and bone mineral density (BMD) DH remain under-described, recommendations for systematic screening osteoporosis are lacking. To describe a large French cohort evaluate association between BMD features osteoporosis. Patients were recruited from Association Gluten Intolerants (AFDIAG) single university dermatology department. A telephone questionnaire was used to...